NCI-H747Homo sapiens (Human)Cancer cell line

Also known as: NCI747, NCIH747, NCI-747, H-747, H747, NCI H747

🤖 AI SummaryBased on 15 publications

Quick Overview

Human colorectal cancer cell line with known mutations and drug sensitivity profiles.

Detailed Summary

The NCI-H747 cell line is a human colorectal cancer cell line derived from a primary tumor. It is widely used in research to study the molecular mechanisms of colorectal cancer and to evaluate the efficacy of targeted therapies. This cell line has been characterized for its genetic mutations, including those in the KRAS, BRAF, and TP53 genes, which are critical in cancer progression. Research on NCI-H747 has contributed to understanding the relationship between genetic alterations and drug response, particularly in the context of 5-fluorouracil and other chemotherapeutic agents. The cell line is also part of large panels used to identify biomarkers for personalized cancer treatment.

Research Applications

Molecular mechanisms of colorectal cancerDrug sensitivity profilingTargeted therapy evaluationBiomarker discovery for personalized treatment

Key Characteristics

KRAS mutationsBRAF mutationsTP53 mutations5-fluorouracil sensitivity
Generated on 6/17/2025

Basic Information

Database IDCVCL_1587
SpeciesHomo sapiens (Human)
Tissue SourceLymph node[UBERON:UBERON_0000029]

Donor Information

Age69
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseaseCecum adenocarcinoma
LineageBowel
SubtypeColon Adenocarcinoma
OncoTree CodeCOAD

DepMap Information

Source TypeATCC
Source IDACH-000403_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg158Leu (c.473G>T)Homozygous-PubMed=30737244
MutationSimpleKRASp.Gly13Asp (c.38G>A)HeterozygousSomaticfrom parent cell line MDA-MB-231
MutationSimpleAPCp.Gln1429Ter (c.4285C>T)Heterozygous-PubMed=20176655
MutationSimpleAPCp.Gln161Ter (c.481C>T)Heterozygous-Unknown, Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,12
D13S317
11,12
D16S539
9,12
D18S51
12
D19S433
14
D21S11
29
D2S1338
17,21
D3S1358
17
D5S818
11
D7S820
10
D8S1179
13,14
FGA
21.2
Penta D
12
Penta E
5,8
TH01
6
TPOX
8,11
vWA
16,19
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Pharmacoproteomic characterisation of human colon and rectal cancer.

Weichert W., Knapp S., Feller S.M., Kuster B.

Mol. Syst. Biol. 13:951-951(2017).

Genomic determinants of protein abundance variation in colorectal cancer cells.

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Cell Rep. 20:2201-2214(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mariadason J.M., Sieber O.M.

Cancer Res. 74:3238-3247(2014).

Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.

Orphanides G., French T., Wessels L.F.A.

BMC Med. Genomics 5:66.1-66.15(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

Br. J. Cancer 103:340-346(2010).

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.

Cancer Res. 70:5901-5911(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Liu Y., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).

Mutations of the BRAF gene in human cancer.";

Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

Nature 417:949-954(2002).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

Characteristics of cell lines established from human colorectal carcinoma.

Johnson B.E., Gazdar A.F.

Cancer Res. 47:6710-6718(1987).

Web Resources